Zoetis Inc (NYSE:ZTS) insider Heidi C. Chen sold 37,453 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total value of $3,034,442.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Zoetis Inc (NYSE:ZTS) traded up $0.15 during trading hours on Wednesday, hitting $80.50. The stock had a trading volume of 3,403,364 shares, compared to its average volume of 3,110,459. The firm has a market cap of $38,689.28, a PE ratio of 46.00, a P/E/G ratio of 1.80 and a beta of 1.07. Zoetis Inc has a twelve month low of $52.25 and a twelve month high of $81.78. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.03. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.47 EPS. research analysts forecast that Zoetis Inc will post 3.02 EPS for the current fiscal year.
Several equities research analysts have weighed in on ZTS shares. Barclays set a $77.00 price target on Zoetis and gave the stock a “hold” rating in a report on Saturday. Deutsche Bank upped their price target on Zoetis from $76.00 to $78.00 and gave the stock a “hold” rating in a report on Friday, February 16th. Piper Jaffray Companies set a $88.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, February 16th. Stifel Nicolaus restated a “buy” rating and set a $86.00 price target (up previously from $84.00) on shares of Zoetis in a report on Friday, February 16th. Finally, Bank of America upped their price target on Zoetis from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Friday, February 16th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. Zoetis has an average rating of “Buy” and an average price target of $79.83.
Several large investors have recently added to or reduced their stakes in ZTS. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Zoetis during the 4th quarter worth about $108,000. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the 3rd quarter worth about $114,000. We Are One Seven LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $120,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after acquiring an additional 1,360 shares in the last quarter. Finally, Premia Global Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $122,000. 94.18% of the stock is owned by institutional investors and hedge funds.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.